Niagen Bioscience (NASDAQ:NAGE) Lowered to “Hold” Rating by Wall Street Zen

Niagen Bioscience (NASDAQ:NAGE) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

NAGE has been the topic of several other research reports. Canaccord Genuity Group lowered their price target on shares of Niagen Bioscience from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Thursday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a report on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Niagen Bioscience Stock Down 0.8%

Niagen Bioscience stock opened at $5.06 on Friday. The firm has a 50 day moving average price of $5.74 and a 200-day moving average price of $7.14. Niagen Bioscience has a twelve month low of $4.72 and a twelve month high of $14.69. The company has a market capitalization of $405.20 million, a P/E ratio of 25.30 and a beta of 2.11.

Institutional Trading of Niagen Bioscience

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Silverberg Bernstein Capital Management LLC bought a new stake in shares of Niagen Bioscience during the 3rd quarter worth $1,169,000. BSW Wealth Partners bought a new position in shares of Niagen Bioscience during the 3rd quarter valued at about $793,000. CWM LLC bought a new position in shares of Niagen Bioscience during the 3rd quarter valued at about $246,000. Precision Wealth Strategies LLC purchased a new position in shares of Niagen Bioscience during the 3rd quarter valued at about $1,527,000. Finally, Allspring Global Investments Holdings LLC purchased a new position in shares of Niagen Bioscience during the 3rd quarter valued at about $144,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

Niagen Bioscience News Summary

Here are the key news stories impacting Niagen Bioscience this week:

• Positive Sentiment: Q4 beat and profit strength — Niagen reported quarterly EPS that topped estimates and stronger-than-expected revenue; media coverage notes the company doubled annual profit and management signaled an acquisition hunt and expansion into GLP‑1-style products, which drove significant after-hours buying interest. Niagen Bioscience Doubles Annual Profit (MSN)
• Positive Sentiment: Quarterly beat confirmed by multiple outlets — Coverage and transcripts highlight strong revenue growth and an EPS beat for Q4, supporting the narrative of improving operations and profitability. NAGE Tops Q4 Earnings (Zacks)
• Neutral Sentiment: Price target tweak but rating intact — Canaccord trimmed its price target from $14 to $13 while maintaining a “buy” rating, signaling continued analyst conviction but a more conservative valuation. Canaccord Price Target Update (Benzinga)
• Neutral Sentiment: HC Wainwright updated multi-quarter and FY2027 EPS models — the firm published a full set of quarterly and FY2027 estimates (FY2027 ~$0.37 EPS), providing a new baseline for investor expectations (mixed across quarters).
• Negative Sentiment: Revenue guidance below street estimates — Niagen issued FY2026 revenue guidance of $142.4M–$148.8M versus a consensus around $153.3M, which reduces near-term top-line visibility and likely pressured the share price despite the quarterly beat. Valuation After New 2026 Guidance (Yahoo)
• Negative Sentiment: Analyst cuts to FY2026 and near-term quarters — HC Wainwright reduced FY2026 EPS (from $0.38 to $0.33) and cut Q2 2026 materially, which may weigh on sentiment as models are reset lower despite stronger Q4 results.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.